Artera Presenting Validation Data at 2025 ASCO Annual Meeting Highlighting How Multimodal AI Platform (MMAI) is Advancing Personalized Cancer Care
The featured oral presentation showcases the first validated MMAI algorithm—used in the ArteraAI Prostate Test —to identify high-risk, non-metastatic prostate cancer patients who are likely to benefit from adding androgen receptor pathway inhibitors (ARPIs) to standard therapy. The STAMPEDE trial helped to establish ARPIs as the standard of care treatment for high-risk patients, but adoption of ARPIs has been uneven, likely due to concerns over side effects and follow-up care.
The study, conducted as part of the STAMPEDE trial, evaluated the addition of ARPIs—specifically abiraterone acetate + prednisolone—to standard androgen deprivation therapy (ADT) and radiation. Artera's model identified that only 25% of high-risk patients derived meaningful benefit from ARPI intensification, suggesting the opportunity to spare up to 75% of this cohort from unnecessary toxicities.
'This data helps answer one of the most critical questions in cancer care: which patients will benefit from added treatment, and which will not,' said Nick James, MD, PhD, Professor of Prostate and Bladder Cancer Research at The Institute of Cancer Research, London, and Consultant Clinical Oncologist at The Royal Marsden NHS Foundation Trust. While traditional tests flag patients at risk of poor outcomes, they don't personalize treatment decisions. Our collaboration with Artera allows us to uncover patterns invisible to the human eye and optimize treatments like never before. The AI tool allows us to connect beneficial treatments to the patient, while sparing those who may suffer unnecessary side effects, or even premature death, if they receive ARPIs they don't need.'
In addition to the oral presentation, Artera will also present a poster featuring external validation of its MMAI platform in men who have undergone radical prostatectomy (RP) for localized prostate cancer. The study demonstrates that the RP MMAI model is an independent prognostic tool for predicting biochemical recurrence (BCR) and long-term outcomes, even when controlling for clinical risk models. Artera's solution works with routine pathology and clinical data and does not require extra tissue or complex molecular testing, making it broadly scalable, cost-effective, and faster to implement.
'We are proud to see Artera's MMAI platform recognized with two abstracts at ASCO, including an oral presentation selected for Best of ASCO,' said Timothy Showalter, Chief Medical Officer of Artera. 'These studies reinforce our commitment to the rigorous clinical validation of the ArteraAI Prostate Test and our broader MMAI platform. Together, they reflect our mission to empower clinicians and patients with personalized, actionable insights that support confident, shared decision-making in prostate cancer care.'
The studies presented by Artera add to the growing body of evidence that its MMAI platform can inform real-time clinical decisions and bring personalized cancer care to broader patient populations. For more information on Artera, visit Artera.ai.
Presentations at the 2025 ASCO Annual Meeting include:
Oral Presentation: Multimodal artificial intelligence (MMAI) model to identify benefit from 2nd-generation androgen receptor pathway inhibitors (ARPI) in high-risk non-metastatic prostate cancer patients from STAMPEDE.
Abstract Number: 5001
Session Type and Title: Oral Session - Genitourinary Cancer—Prostate, Testicular, and Penile
Date and Time: Tuesday, June 3rd at 9:45 a.m. CT
Poster Presentation: External validation of a pathology-based multimodal artificial intelligence biomarker for predicting prostate cancer outcomes after prostatectomy.
Abstract Number: 5106
Session Type and Title: Poster Session - Genitourinary Cancer—Prostate, Testicular, and Penile
Date and Time: Monday, June 2nd at 9:00 a.m. CT
About Artera
Artera is a leading precision medicine company developing AI tests to personalize cancer therapy. Artera offers an AI-enabled test that is the first of its kind to provide both prognostic and predictive results for patients with localized prostate cancer: ArteraAI Prostate Test.
Artera's multimodal artificial intelligence (MMAI) biomarker test leverages a unique algorithm that assesses digital images from a patient's biopsy and their clinical data. The AI combines this information to determine their prognosis and predict whether a patient will benefit from a particular therapy and has been validated using many Phase 3 randomized trials.
Artera's laboratory is CLIA-certified and College of American Pathologists (CAP) accredited. The ArteraAI Prostate Test is clinically available through Artera's laboratory in Jacksonville, Florida, and can be ordered online at artera.ai.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
12 hours ago
- Business Wire
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation ('Quanterix' or the 'Company') (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced that on July 8, 2025, the Company approved inducement grants of restricted stock units ('RSUs') representing 267,269 shares of Quanterix common stock to twenty employees newly-hired in connection with the acquisition of Akoya Biosciences, Inc. The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with the Company. The RSUs vest in full on the one year anniversary of the grant date, subject to the applicable individual's continued employment with the Company or one of its subsidiaries through the vesting date. About Quanterix Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa ® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With more than 3,400 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company ®, adding multiplexed tissue imaging with single-cell resolution to its portfolio. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue—advancing precision medicine from discovery to diagnostics. Learn more at
Business Wire
18 hours ago
- Business Wire
CareView Communications Launches Partnership with Memorial Hospital Biloxi to Enhance Virtual Sitting Services
LEWISVILLE, Texas--(BUSINESS WIRE)--CareView Communications, Inc., a leading provider of virtual care and patient monitoring solutions ('CareView' or the 'Company') (OTCQB: CRVW), is proud to announce a new partnership with Memorial Hospital Biloxi to improve patient care through advanced virtual sitting technology. This collaboration allows Memorial Hospital Biloxi to leverage CareView's latest state-of-the-art platform. This platform uses predictive technology to enhance care coordination, reduce patient risk, and empower clinical teams to observe patients in real-time from a centralized location. The partnership reflects a shared commitment to delivering high-quality, technology-enabled care to patients across the Gulf Coast region. 'We are excited to partner with Memorial Hospital Biloxi, an organization that shares our passion for patient-centered innovation,' said Sandra McRee, Chief Operating Officer at CareView Communications. 'Together, we will expand access to care, improve clinical outcomes, and support patients by providing enhanced observation and safety through our virtual sitting solution.' CareView's solutions provide real-time visual monitoring, fall-risk alerts, and communication tools that enable staff to intervene quickly and proactively. This information enables Memorial Hospital Biloxi's care teams to reduce adverse events, optimize staffing, and ensure a safer patient environment. Implementing CareView's technology is part of Memorial Hospital Biloxi's broader initiative to invest in digital health solutions that improve operational efficiency while maintaining the highest standards of patient care. For more information about CareView's virtual care solutions, visit About CareView Communications Inc. CareView has been dedicated to supporting hospital care teams for over a decade with its innovative virtual care solutions. The Company has established successful partnerships with over 200 hospitals nationwide, implementing effective inpatient virtual care strategies that greatly enhance patient safety and overcome critical staffing challenges. The CareView platform, fueled by industry-leading predictive technology and supported by its purpose-built hardware, specifically addresses the unique requirements of virtual nursing and virtual sitting use cases. The CareView team works closely with their hospital partners to understand their evolving needs and deliver tailored virtual care strategies that align with their objectives. By providing healthcare professionals with the tools they need to deliver exceptional care, CareView contributes to improved patient outcomes and a more sustainable healthcare ecosystem. Learn more at or follow CareView on LinkedIn. About Memorial Hospital Biloxi Memorial Hospital Biloxi is a not-for-profit, multi-facility healthcare system serving the Mississippi Gulf Coast. With a commitment to excellence, innovation, and community care, Memorial provides a comprehensive range of medical services, including advanced primary and specialty care, across its network of providers and facilities.
Business Wire
20 hours ago
- Business Wire
HCA Healthcare Appoints John W. Chidsey, III as New Independent Director
NASHVILLE, Tenn.--(BUSINESS WIRE)-- HCA Healthcare, Inc. (NYSE: HCA), one of the nation's leading healthcare providers, today announced that its board of directors has appointed John W. Chidsey, III as an independent director, effective July 15, 2025. With his addition, HCA Healthcare's board of directors increases from nine to ten members. Mr. Chidsey will serve as a member of HCA Healthcare's audit and compliance committee, compensation committee and patient safety and quality of care committee. Mr. Chidsey most recently served as the global chief executive officer of Subway. He previously served as chief executive officer of Burger King Holdings, Inc. and held significant leadership roles at Cendant Corporation. Earlier in his career, he also held various senior financial leadership roles at PepsiCo. Mr. Chidsey also currently serves on the board of Norwegian Cruise Line Holdings Ltd. and previously served on the boards of Encompass Health Corporation, Burger King Holdings, Inc. (as chairman) and Brinker International, Inc. 'John Chidsey's distinguished career demonstrates his extensive experience in leading corporate strategy at large, complex public and private companies, and we are confident he will provide invaluable insight as a board member,' said Thomas F. Frist III, chairman of the board of HCA Healthcare. 'John's financial, operational and executive leadership experience and expertise will complement HCA Healthcare's commitment to the care and improvement of human life. We are pleased to announce his addition to our board.' Mr. Chidsey holds a B.A. degree from Davidson College, as well as MBA and J.D. degrees from Emory University. About HCA Healthcare Nashville-based HCA Healthcare is one of the nation's leading providers of healthcare services comprising 192 hospitals and approximately 2,500 ambulatory sites of care, including surgery centers, freestanding ERs, urgent care centers, and physician clinics, in 20 states and the United Kingdom. With its founding in 1968, HCA Healthcare created a new model for hospital care in the United States, using combined resources to strengthen hospitals, deliver patient-focused care and improve the practice of medicine. HCA Healthcare has conducted a number of clinical studies, including one that demonstrated that full-term delivery is healthier than early elective delivery of babies and another that identified a clinical protocol that can reduce bloodstream infections in ICU patients by 44%. HCA Healthcare is a learning health system that uses its approximately 44 million annual patient encounters to advance science, improve patient care and save lives. All references to 'Company,' 'HCA' and 'HCA Healthcare' as used throughout this document refer to HCA Healthcare, Inc., and its affiliates.
